Omega-3 Fatty Acids Survey in Men under Active Surveillance for Prostate Cancer: from Intake to Prostate Tissue Level
Nutrients 2019, 11(7), 1616; https://doi.org/10.3390/nu11071616
Items in both categories Prostate Cancer and Omega-3 are listed here:
- 2.5 X reduced risk of cancer in 70 year-olds by a small amount of Vitamin D, Omega-3 and exercise – RCT April 2022
- Prostate Cancer PSA reduced by 60 ng of Vitamin D, Vitamin B complex, Omega-3, Curcumin and diet – June 2021
- Men with High Omega-3 ratio 3 times less likely to have high grade prostate cancer – July 2019
- Low-Grade Prostate Cancer 70 percent less likely to progress if good level of Omega-3 – June 2018
- Prostate Cancer treatment (Vitamin D, Omega-3, Tumeric) RCT ending Dec 2018
Vitamin D and Omega-3 category starts with
CIlck here for details
- Breast Cancer reduced 20 percent by fish (Omega-3) – meta-analysis Feb 2019
- Omega-3 reduces side effects of Cancer treatments – April 2019
- Omega-3 prevents and treats several cancers – Sept 2017
- Pancreatic Cancer is increasing – Vitamin D and Omega-3 should reduce the risk
- Omega-3 should help Pancreatic Cancer in 5 ways – June 2017
- Prostate Cancer treatment (Vitamin D, Omega-3, Tumeric) RCT ending Dec 2018
Download the PDF from VitaminDWiki
Dietary omega-3 fatty acids (ω3), particularly long-chain ω3 (LCω3), have protective effects against prostate cancer (PCa) in experimental studies. Observational studies are conflicting, possibly because of the biomarker used. This study aimed at evaluating associations between grade reclassification and ω3 levels assessed in prostatic tissue, red blood cells (RBC), and diet. We conducted a validation cross-sectional study nested within a phase II clinical trial. We identified 157 men diagnosed with low-risk PCa who underwent a first active surveillance repeat prostate biopsy session. Fatty acid (FA) intake was assessed using a food frequency questionnaire and their levels measured in prostate tissue and RBC. Associations were evaluated using logistic regression. At first repeat biopsy session, 39 (25%) men had high-grade PCa (grade group ≥2). We found that high LCω3-eicosapentaenoic acid (EPA) level in prostate tissue (odds ratio (OR) 0.25; 95% (confidence interval (CI) 0.08–0.79; p-trend = 0.03) was associated with lower odds of high-grade PCa. Similar results were observed for LCω3 dietary intake (OR 0.30; 95% CI 0.11-0.83; p-trend = 0.02) but no association for RBC. LCω3-EPA levels in the target prostate tissue are inversely associated with high-grade PCa in men with low-risk PCa, supporting that prostate tissue FA, but not RBC FA, is a reliable biomarker of PCa risk.
| 3578 visitors, last modified 20 Jul, 2019, |